|
OALib Journal期刊
ISSN: 2333-9721
费用：99美元
|
|
|
|
以度鲁特韦为基础药物的抗hiv-1体外药效学研究
, PP. 50-58
Keywords: hiv-1,度鲁特韦,联合用药,药物协同作用
Abstract:
本文以研究度鲁特韦(dolutegravir,dtg)为基础药物抗hiv-1体外药效学为目的,以野生hiv-1、核苷类逆转录酶抑制剂耐药hiv-1(hiv-1rt-d67n,k70r,t215f)及整合酶抑制剂耐药hiv-1(hiv-1in-g140s,q148h)重组病毒模型为代表,首先比较了整合酶抑制剂与非核苷类逆转录酶抑制剂作为基础药物联合用药的体外药效学;本研究还比较了度鲁特韦和雷特格韦(raltegravir,ral)分别与两个核苷类逆转录酶抑制剂联合用药的体外药效学。结果显示,以整合酶抑制剂dtg为基础药物抑制野生hiv-1的药效优于非核苷类逆转录酶抑制剂,与ral效果相当;以dtg为基础药物对核苷类逆转录酶抑制剂耐药病毒(hiv-1rt-d67n,k70r,t215f)的药效与依法韦伦(efavirenz,efv)和奈韦拉平(nevirapine,nvp)相近;对整合酶抑制剂耐药病毒(hiv-1in-g140s,q148h)的药效优于ral。本研究明确了dtg联合用药的体外药效学,研究结果为临床选择药物提供了实验数据。
| [1] | sepkowitzka.aids-thefirst20years[j].nengljmed,2001,344:1764-1772.
|
| [2] | cunninghamal,donaghyh,harmanan,etal.manipulationofdendriticcellfunctionbyviruses[j].curropinmicrobiol,2010,13:524-529.
|
| [3] | ramanaln,anandar,sethuramans,etal.targetingstrategiesfordeliveryofanti-hivdrugs[j].jcontrolrelease,2014,192c:271-283.
|
| [4] | kulkarnir,hluhanichr,mccolldm,etal.thecombinedanti-hiv-1activityofemtricitabineandtenofovirwiththeintegraseinhibitorselvitegravirorraltegravirshowhighlevelsofsynergyinvitro[j].antimicrobagentschemother,2014,58:6145-6150.
|
| [5] | worldhealthorganization.consolidatedguidelinesontheuseofantiretroviraldrugsfortreatingandpreventinghivinfection[s].geneva:whopress,2013:28-30.
|
| [6] | zhangfj,wangj,wangfs,etal.thenationalfreeantiretroviraltreatmentofaidshandbook(国家免费艾滋病抗病毒药物治疗手册)[m].3rded.beijing:people'smedicalpublishinghouse,2012:55.
|
| [7] | whitneyjb,limsy,wainbergma.evolutionarymechanismsofretroviralpersistence[j].aidsrev,2011,13:234-239.
|
| [8] | wainbergma,zaharatosgj,brennerbg.developmentofantiretroviraldrugresistance[j].nengljmed,2011,365:637-646.
|
| [9] | stanforduniversity.nnrtimutationpattern&susceptibility[eb/ol].2014-09-03.http://hivdb.stanford.edu/pages/phenosummary/pheno.nnrti.simple.html.
|
| [10] | pommiery,marchandc,neamatin.retroviralintegraseinhibitorsyear2000:updateandperspectives[j].antivirres,2000,47:139-148.
|
| [11] | caoyl,lisx,chenh,etal.establishmentofpharmacologicalevaluationsystemfornon-nucleosidereverse-transcriptaseinhibitorsresistanthiv-1[j].actapharmsin(药学学报),2009,44:355-361.
|
| [12] | caoyl,guoy.screeningofhiv-1replicationinhibitorsbyusingpseudotypedvirussystem[j].actapharmsin(药学学报),2008,43:253-258.
|
| [13] | choutc.theoreticalbasis,experimentaldesignandcomputerizedsimulationofsynergismandantagonismindrugcombinationstudies[j].pharmacolrev,2006,58:621-681.
|
| [14] | brehmjh,koontzd,meteerjd,etal.selectionofmutationsintheconnectionandrnasehdomainsofhumanimmunodeficiencyvirustype1reversetranscriptasethatincreasesresistanceto3′-azido-3′-dideoxythymidine[j].jvirol,2007,81:7852-7859.
|
| [15] | rawalrk,murugesanv,kattisb.structure-activityrelationshipstudiesonclinicallyrelevanthiv-1nnrtis[j].currmedchem,2012,19:5364-5380.
|
| [16] | stanforduniversity.inimutationpattern&susceptibility[eb/ol].2014-09-03.http://hivdb.stanford.edu/pages/phenosummary/pheno.ini.simple.html.
|
| [17] | kobayashim,yoshinagat,sekit,etal.invitroantiretroviralpropertiesofs/gsk1349572,anext-generationhivintegraseinhibitor[j].antimicrobagentschemother,2011,55:813-821.
|
| [18] | fda.antiretroviraldrugsusedinthetreatmentofhivinfection[eb/ol].2014-09-03.http://www.fda.gov/forpatients/illness/hivaids/treatment/ucm118915.htm.
|
| [19] | karmonsl,markowitzm.next-generationintegraseinhibitors[j].drugs,2013,73:213-228.
|
Full-Text
|
|
Contact Us
service@oalib.com QQ:3279437679 
WhatsApp +8615387084133
|
|
